Alert: Anticipated FDA REMS Programs to Impact Psychedelic Therapy Delivery

As FDA approvals for psychedelic therapies draw closer, new Risk Evaluation and Mitigation Strategies (REMS) are highly anticipated. These programs are expected to extend beyond basic safety measures, potentially requiring certified healthcare settings, extensive provider training, patient registries, and specific monitoring periods. The implementation of such comprehensive REMS will profoundly influence operational capacity, provider participation, and overall patient access within the psychedelic therapy market.